Recipharm has unveiled a multi-million-dollar investment in its US operations aimed at increasing sterile fill and finish manufacturing capacity for biologics and advanced therapies. The expansion comes after the company secured a clinical biologics fill and finish agreement with a major global pharmaceutical company and is intended to broaden capabilities spanning development, scale-up, clinical production and commercial manufacturing. Through the investment, Recipharm plans to provide pharmaceutical and biotechnology companies with greater access to manufacturing services in the United States while strengthening support for programs at different stages of the product lifecycle.
According to the company, the investment will enhance manufacturing infrastructure and technical expertise across its US network. Recipharm said the initiative is designed to support customers from early development through commercial supply by increasing capacity, accelerating development timelines and improving access to domestic manufacturing resources. The company stated that the expanded platform will help meet growing requirements for biologics and advanced therapies while reinforcing its position in US Sterile Manufacturing. The announcement follows the recently signed clinical biologics fill and finish agreement, which Recipharm said demonstrates continuing demand for manufacturing solutions and domestic capacity dedicated to biologics and advanced therapies.
Commenting on the expansion, Greg Behar, CEO of Recipharm, said: “The demand for biologics and advanced therapies continues to accelerate, and manufacturers must be ready to meet that challenge with the right capacity, expertise and technology. By expanding our sterile manufacturing capabilities, we are investing in the infrastructure needed to support the next wave of pharmaceutical innovation.”
Recipharm also reported enhancements to its aseptic manufacturing platform to support both clinical and commercial programmes in North America and Europe. As part of the broader expansion, the company is extending its sterile manufacturing and contract manufacturing services to include API compounding, analytical transfer and validation, process characterisation, process performance qualification (PPQ), and aseptic fill and finish manufacturing. These additions complement existing US capabilities covering nucleic acids, RNA, lipid nanoparticle development and manufacturing, analytical services, bacterial cell banking, and sterile fill and finish operations. Through these upgrades, the company aims to strengthen its role in US Sterile Manufacturing and support customers seeking integrated development and production services.
